BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/30/2019 2:18:31 AM | Browse: 190 | Download: 200
Publication Name World Journal of Clinical Oncology
Manuscript ID 47564
Country/Territory Singapore
2019-03-19 01:34
Peer-Review Started
2019-03-19 14:59
To Make the First Decision
2019-08-06 06:37
Return for Revision
2019-08-08 08:04
2019-08-14 00:40
Second Decision
2019-08-21 08:44
Accepted by Journal Editor-in-Chief
Accepted by Company Editor-in-Chief
2019-08-21 23:18
Articles in Press
2019-08-21 23:18
Publication Fee Transferred
Edit the Manuscript by Language Editor
2019-08-28 13:42
Typeset the Manuscript
2019-09-04 01:18
Publish the Manuscript Online
2019-09-30 02:18
ISSN 2218-4333 (online)
Open Access This is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/
Copyright © The Author(s) 2019. Published by Baishideng Publishing Group Inc. All rights reserved.
Article Reprints For details, please visit: http://www.wjgnet.com/bpg/gerinfo/247
Permissions For details, please visit: http://www.wjgnet.com/bpg/gerinfo/207
Publisher Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
Website http://www.wjgnet.com
Category Oncology
Manuscript Type Editorial
Article Title Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma
Manuscript Source Invited Manuscript
All Author List Jianbiao Zhou and Wee-Joo Chng
Author(s) ORCID Number
Jianbiao Zhou http://orcid.org/0000-0002-5679-671X
Wee-Joo Chng http://orcid.org/0000-0003-2578-8335
Funding Agency and Grant Number
Corresponding author Jianbiao Zhou, MD, PhD, Senior Scientist, Cancer Science Institute of Singapore, National University of Singapore, Centre for Translational Medicine, 28 Medical Drive, Singapore 117456, Singapore. csizjb@nus.edu.sg
Keywords Multiple myeloma; Proteasome inhibitor; Bortezomib; Proteasome β5-subunit; Drug resistance; Clonal evolution
Core Tip Multiple myeloma (MM) is the second common hematologic malignancy. An array of new treatments has been approved over the last decade. Hence, the survival of MM patients has improved steadily. Among these new drugs, the first-in-class proteasome inhibitor bortezomib has been revolutionary for targeted therapy. Now bortezomib is the backbone for treating MM. However, emerging drug resistance poses a major challenge for clinicians to use proteasome inhibitors. In this editorial, we discuss proteasome β5-subunit mutations as a novel resistant mechanism to bortezomib and its implication in tracking clonal evolution and suggest potential strategies to overcome drug resistance.
Publish Date 2019-09-30 02:18
Citation Zhou J, Chng WJ. Novel mechanism of drug resistance to proteasome inhibitors in multiple myeloma. World J Clin Oncol 2019; 10(9): 303-306
Url https://www.wjgnet.com/2218-4333/full/v10/i9/303.htm
DOI https://dx.doi.org/10.5306/wjco.v10.i9.303
Full Article (PDF) WJCO-10-303.pdf
Full Article (Word) WJCO-10-303.docx
Manuscript File 47564-Review_Edited.doc
Answering Reviewers 47564-Answering reviewers.pdf
Audio Core Tip 47564-Audio core tip.m4a
Conflict-of-Interest Disclosure Form 47564-Conflict-of-interest statement.pdf
Copyright License Agreement 47564-Copyright license agreement.pdf
Peer-review Report 47564-Peer-review(s).pdf
Scientific Misconduct Check 47564-Scientific misconduct check.pdf
Scientific Editor Work List 47564-Scientific editor work list.pdf